BAIYUNSHAN PH - An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section

The Company does not make any statement and expressly disclaims any liability arising out of or in reliance upon the whole or any part of the contents of this announcement. assumes no responsibility for any losses caused by the content.

Overseas regulatory announcement

This announcement is made in accordance with Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

This is to publish the information published by Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. (the "Company") on the website of the Shanghai Stock Exchange (www.sse.com.cn)

The full Chinese text of the 2025 report of the Audit Committee of the Ninth Board of Directors of the Company on the Performance of Supervision Responsibilities of the Accounting Firm in Chinese, only For reference.

Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. board of directors

Guangzhou, China, March 20, 2026

As of the date of this announcement, the company’s board of directors includes executive directors Mr. Li Xiaojun, Mr. Chen Jiehui, Mr. Cheng Hongjin and Mr. Tang Heping. and Mr. Li Hong, and independent non-executive directors Mr. Chen Yajin, Mr. Huang Min, Mr. Huang Longde and Ms. Sun Baoqing.

Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd.

Audit Committee of the Ninth Board of Directors Review of Accounting Firms in 2025

Report on performance of supervisory responsibilities

According to the "Company Law of the People's Republic of China" and the "Securities Law of the People's Republic of China"

"Code of Governance of Listed Companies" "Selection of Accountants by State-owned Enterprises and Listed Companies"

"Regulations on the Administration of Securities Exchanges" and "Shanghai Stock Exchange Self-Regulatory Guidelines for Listed Companies No. 1"

——Standardized Operation" and Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. (hereinafter referred to as

(referred to as the "Company" or "the Company"), the Articles of Association and the Audit Committee of the Board of Directors shall

"Details" and other regulations and requirements, the Audit Committee of the Ninth Board of Directors acted diligently and diligently

principles, fulfill their duties conscientiously, and perform their duties conscientiously. The 2025 annual meeting of the Audit Committee will now be

The accounting firm’s performance of supervisory responsibilities is reported as follows:

1. Basic situation of accounting firms in 2025 annual audit

(1) Basic information of accounting firms

Dasin has 33 branches across the country and set up a branch in Hong Kong.

In 2017, Daxin International Accounting Network was established, which currently has offices in the United States, Canada,

There are 48 network member firms in Australia, Germany, France, the United Kingdom, and Singapore. Big

Xinxin is one of the earliest accounting firms engaged in securities services business in China and one of the first batch of

He is qualified to audit H-share companies and has nearly 30 years of experience in the securities business.

The chief partner of Daxin is Mr. Xie Zemin. As of December 31, 2025,

Among Daxin’s employees, there are 182 partners and 1,053 certified public accountants. CPA

Among the divisions, more than 500 people have signed the securities service business audit report.

(2) Procedures for appointing an accounting firm

The 2nd meeting of the Company’s Ninth Audit Committee in 2025 and the Ninth Board of Directors

The 23rd meeting and the 2024 Annual General Meeting of Shareholders reviewed and approved the "About Renewal of Appointment"

Daxin Accounting Firm (Special General Partnership) is the company’s 2025 annual financial Proposal of the Audit Institution" and "About Re-appointment of Daxin Accounting Firm (Special Ordinary)

Partnership) shall be the company’s internal control and audit institution in 2025.”

2. Duty performance of the accounting firm in the 2025 annual audit

In the process of performing the audit work, the company’s management and governance members discussed with Daxin

Independence of the firm and relevant auditors, audit plan, risk judgment, risks

and fraud testing and evaluation methods, annual audit focus, audit adjustment matters, preliminary

We communicated the audit opinions, etc. and believed that the Daxin audit working group has the ability to implement this audit.

The professional knowledge and professional qualifications of accounting work enable them to be competent for this audit work. follow

"Audit Engagement Letter", combined with the company's 2025 annual report work arrangements, Daxin

The company’s 2025 annual financial report and the effectiveness of internal controls were audited and issued

issued a standard unqualified audit report; at the same time, the company’s internal control audit

status, capital occupation by controlling shareholders and other related parties, continuing related transactions,

The storage and actual use of raised funds shall be verified and verified, and a professional certificate shall be issued. item report.

3. Supervision of accounting firms by the audit committee

In accordance with the company's "Implementation Rules of the Audit Committee of the Board of Directors" and other relevant regulations, the review

The accounting committee’s performance of supervisory responsibilities over the accounting firm is as follows:

In the selection of accounting firms, the Audit Committee was very impressed by Daxin’s professionalism.

Qualifications, business capabilities, integrity status, independence, etc. have been strictly verified and evaluated.

It is believed that it has qualifications such as securities and futures-related business licenses and is qualified to be a listed company

Professional qualifications and competencies for providing audit services. No project member has violated the

The National Code of Professional Ethics for Certified Public Accountants stipulates the independence requirements and has sufficient

The independence, integrity and investor protection capabilities of the company can meet the company's 2025

Requirements for annual financial audit work and internal control audit work in 2025. In the company's

At the second meeting of the ninth session of the Board of Directors in 2025, the Audit Committee reviewed the "About the Continuation of Appointed Daxin Accounting Firm (Special General Partnership) as the company’s annual financial accountant for 2025

Proposal on the Re-appointment of Daxin Accounting Firm (Special General Accounting Firm)

"Proposal on the establishment of the Company's internal control and audit institution in 2025", and it is agreed that the above-mentioned

The proposal is submitted to the company's board of directors for review.

4. Overall evaluation

The Audit Committee of the Ninth Board of Directors strictly complies with the requirements of the China Securities Regulatory Commission and the Shanghai Securities Exchange

Securities Exchange, The Stock Exchange of Hong Kong Limited and the Articles of Association and the Audit Committee of the Board of Directors

"Committee Implementing Rules", "Working Rules for Special Meetings of Independent Directors" and other relevant provisions,

Give full play to the role of professional committees and review the relevant qualifications and practices of accounting firms.

ability, etc., and discussed with the accounting firm during the annual report audit.

discuss and communicate, and urge accounting firms to issue timely, accurate, objective and fair

The audit report has effectively fulfilled the audit committee's supervisory responsibilities over the accounting firm.

Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd.

audit committee

March 20, 2026